KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Gains from Investment Securities: 2020-2025

Historic Gains from Investment Securities for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to $2.4 million.

  • Recursion Pharmaceuticals' Gains from Investment Securities rose 141.76% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.9 million, marking a year-over-year decrease of 286.57%. This contributed to the annual value of -$7.6 million for FY2024, which is 123.86% down from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Gains from Investment Securities stood at $2.4 million, which was up 152.06% from -$4.7 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $5.9 million during Q2 2024, with a 5-year trough of -$8.2 million in Q4 2024.
  • For the 3-year period, Recursion Pharmaceuticals' Gains from Investment Securities averaged around -$1.6 million, with its median value being -$4.3 million (2023).
  • Per our database at Business Quant, Recursion Pharmaceuticals' Gains from Investment Securities slumped by 1,530.72% in 2021 and then soared by 4,732.50% in 2023.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Gains from Investment Securities stood at -$1.2 million in 2021, then slumped by 313.14% to -$4.8 million in 2022, then rose by 5.84% to -$4.5 million in 2023, then slumped by 82.89% to -$8.2 million in 2024, then surged by 141.76% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, -$4.7 million for Q2 2025, and -$4.4 million during Q1 2025.